By Karen Bernstein

When Michael Casey joined Matrix Pharmaceutical Inc. in September 1997, he liked the company's IntraDose technology for local delivery of cancer treatments, and he liked the fact that MATX had $70 million in cash. But he wasn't as enthusiastic about MATX's AccuSite product for genital warts, and he felt the company needed more products and better focus.